Latest News
Bayer reports positive Phase III FIND-CKD results for Kerendia in non-diabetic chronic kidney disease
5 June 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) on Friday reported full results from the Phase III FIND-CKD trial evaluating Kerendia (finerenone) in adults with non-diabetic chronic kidney disease (nd-CK...
Tandem Diabetes Care receives CE mark for expanded automated insulin delivery indications in Europe
5 June 2026 - Insulin delivery and diabetes technology company Tandem Diabetes Care Inc (Nasdaq:TNDM) announced on Friday that it has received CE mark approval in Europe for expanded indications of its automated insulin delivery systems, enabling use...
Owkin to build AI agents as part of K Pro collaboration with Sanofi
5 June 2026 - Agentic AI company Owkin announced on Friday that it has entered into a multi-year collaboration with French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) to co-develop next-generation biopharma agents, supported by a...
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
5 June 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq: GILD) and biotechnology company Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT), formerly known as Galapagos, confirmed late Thursday the successful completion of the pre...
Lupin's Ranluspec (ranibizumab) injection receives US FDA approval
5 June 2026 - India-based global pharmaceutical company Lupin Limited (BSE: 500257) (NSE: LUPIN) announced on Thursday that the US Food and Drug Administration (FDA) has approved its ranibizumab, Ranluspec (ranibizumab-hkdz), as an interchangeable bi...